Comparative Effectiveness of Complement-Targeted Therapies for C3 Glomerulopathy: A Systematic Review and Bayesian Network Meta-Analysis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0678; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Results A total of four RCTs including 265 patients and evaluating pegcetacoplan, iptacopan, avacopan, and danicopan were included. Differences between leading therapies remained uncertain, although pegcetacoplan ranked highest overall. These findings may inform management of C3G and IC-MPGN but highlight the need for longer-term comparative studies."
HEOR • Retrospective data • Review • Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease
|
|
Anu Kaskinen; Priyanka Khandelwal; Arenn Singh Jauhal; Christopher J. Patriquin; Christoph Licht; Cal Robinson
|